Empagliflozin/Linagliptin: A Review in Type 2 Diabetes

Drugs
Esther S Kim, Emma D Deeks

Abstract

Empagliflozin/linagliptin (Glyxambi(®)) is a once-daily sodium glucose co-transporter type 2 (SGLT2) inhibitor and dipeptidyl peptidase (DPP)-4 inhibitor fixed-dose combination product that is approved in the USA as an adjunct to diet and exercise in adults with type 2 diabetes (T2D) when treatment with both empagliflozin and linagliptin is appropriate. This article reviews the clinical efficacy and tolerability of oral empagliflozin/linagliptin in patients with T2D and summarizes the pharmacological properties of the agents. Results of two randomized controlled trials of 52 weeks' duration in adults with T2D demonstrated that empagliflozin/linagliptin improved glycaemic control significantly more than linagliptin when administered as initial therapy (whereas results vs. empagliflozin were mixed in this setting) and significantly more than linagliptin or empagliflozin when administered as an add-on therapy to metformin. In addition to glycaemic control, empagliflozin/linagliptin provided significant weight loss compared with linagliptin in both trials. Empagliflozin/linagliptin was generally well tolerated in patients with T2D, with a low risk of hypoglycaemia and no reports of exacerbations of, or hospitalizations for, heart f...Continue Reading

References

Dec 17, 2008·Pharmacological Reviews·Wook Kim, Josephine M Egan
Jan 21, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Stefan BlechKlaus Wagner
May 29, 2010·Nature Reviews. Drug Discovery·Edward C Chao, Robert R Henry
Jan 14, 2011·The American Journal of Medicine·Bernard Zinman
Feb 11, 2011·British Journal of Clinical Pharmacology·Arne RingKlaus A Dugi
Jan 17, 2012·British Journal of Clinical Pharmacology·Ulrike Graefe-ModyHans-Juergen Woerle
Jan 25, 2012·Advances in Therapy·Lawrence Blonde, Zinnia T San Juan
Sep 19, 2012·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Thomas RauchTim Heise
Sep 28, 2012·Diabetes, Obesity & Metabolism·D S H Bell
Apr 26, 2013·The New England Journal of Medicine·Mohammed K AliEdward W Gregg
Jul 11, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Tim HeiseKlaus Dugi
Jan 28, 2014·The Journal of Clinical Investigation·Ele FerranniniHans-Juergen Woerle
Dec 3, 2014·Clinical Therapeutics·Peter Clifton
Feb 11, 2015·The Annals of Pharmacotherapy·Linda TranErin E Thompson
Apr 17, 2015·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberMichael H Davidson
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group

❮ Previous
Next ❯

Citations

Mar 24, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Ildiko Lingvay
Mar 26, 2021·Molecular Biology Reports·Amit GuptaAbdul Hafeez

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.